Document is current
Any future updates will be listed below
-
Authors
Magrini, Elena
Di Marco, Sabrina
Mapelli, Sarah N. https://orcid.org/0000-0002-0129-2055
Perucchini, Chiara
Pasqualini, Fabio
Donato, Alessia
Guevara Lopez, Maria de la Luz
Carriero, Roberta
Ponzetta, Andrea
Colombo, Piergiuseppe
Cananzi, Ferdinando https://orcid.org/0000-0002-8227-3373
Supino, Domenico
Reis, Edimara S.
Peano, Clelia https://orcid.org/0000-0001-7055-3629
Inforzato, Antonio
Jaillon, Sebastien
Doni, Andrea
Lambris, John D.
Mantovani, Alberto https://orcid.org/0000-0001-5578-236X
Garlanda, Cecilia https://orcid.org/0000-0002-1510-7703
- License Information
-
More Information
Article History
Received: 23 January 2020
Accepted: 15 January 2021
First Online: 18 February 2021
Competing interests
: All authors except for J.D.L. declare no competing interests. J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes and is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. J.D.L. is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives such as APL-2/pegcetacoplan).
